Seres Therapeutics
serestherapeutics.com
Microbiome
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Seres Therapeutics stock holds steady as investors await next catalysts
Seres Therapeutics stock trades near recent levels on Nasdaq as of September 18, 2026, with investors focused on earlier microbiome therapy trial data. The latest reported figures from the company provide the context for current valuation and risk assessm
Read more
Report
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (
Read more
Report
Seres Therapeutics: $25 Million Deal And Lease Restructuring Extend Cash Runway Into Q1 2027
Seres Therapeutics announced two strategic transactions designed to strengthen its balance sheet, lower operating expenses, and extend its projected cash runway well into the first quarter of 2027.
Read more
Report
Seres Therapeutics Stock: Speculative Biotech Turns Quiet After Roller-Coaster Year
Seres Therapeutics has slipped into near-silence on the ticker tape, with its shares trading at penny-stock levels after a brutal year for investors. Yet under the surface, the microbiome pioneer still carries binary upside risk tied to its VOWST franchis
Read more
Report
Seres Therapeutics Stock: Speculative Biotech Turns Quiet After Roller-Coaster Year
Seres Therapeutics has slipped into near-silence on the ticker tape, with its shares trading at penny-stock levels after a brutal year for investors. Yet under the surface, the microbiome pioneer still carries binary upside risk tied to its VOWST franchis
Read more
Report
Seres Therapeutics outlines Phase II SER-155 trial plans as company extends cash runway through Q2 2026
Read more
Report
Seres Therapeutics, Inc.
Key Insights The considerable ownership by individual investors in Seres Therapeutics indicates that they collectively...
Read more
Report
Show more news